度戈妥珠單抗

化合物

度戈妥珠單抗INN:Duligotuzumab)是一種雙特異性人源化IgG1單克隆抗體,設計用於治療癌症。它充當免疫調節劑並與EGFR和HER3英語ERBB3結合。[1][2]它由羅氏公司開發。針對頭頸癌結直腸癌的臨床開發已停止,但與考比替尼聯合使用的I期試驗正在評估實體瘤治療的安全性。[3]

度戈妥珠單抗
單克隆抗體
種類完整抗體
目標HER3英語ERBB3
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號1314238-96-4
ChemSpider
  • none
UNII
KEGG

參考資料

  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-22]. (原始內容存檔 (PDF)於2016-03-04). 
  2. ^ Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Alfonso, Pilar Garcia; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Jeffery, Mark; Bartolomeo, Maria Di. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2018-05-15, 24 (10) [2024-01-22]. ISSN 1557-3265. PMID 29506988. doi:10.1158/1078-0432.CCR-17-0646. (原始內容存檔於2024-03-14). 
  3. ^ Duligotuzumab. AdisInsight. [2024-01-22]. (原始內容存檔於2021-11-19).